ArticleJMIR medical informatics2024
Using Machine Learning to Predict the Duration of Atrial Fibrillation: Model Development and Validation.
Article in JMIR medical informatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtrial fibrillation (AF) is a progressive disease, and its clinical type is classified according to the AF duration: paroxysmal AF, persistent AF (PeAF; AF duration of less than 1 year), and long-standing persistent AF (AF duration of more than 1 year). When considering the indication for catheter ablation, having a long AF duration is considered a risk factor for recurrence, and therefore, the duration of AF is an important factor in determining the treatment strategy for PeAF.
objectiveThis study aims to improve the accuracy of the cardiologists' diagnosis of the AF duration, and the steps to achieve this goal are to develop a predictive model of the AF duration and validate the support performance of the prediction model.
methodsThe study included 272 patients with PeAF (aged 20-90 years), with data obtained between January 1, 2015, and December 31, 2023. Of those, 189 (69.5%) were included in the study, excluding 83 (30.5%) who met the exclusion criteria. Of the 189 patients included, 145 (76.7%) were used as training data to build the machine learning (ML) model and 44 (23.3%) were used as test data for predictive ability of the ML model. Using a questionnaire, 10 cardiologists (group A) evaluated whether the test data (44 patients) included AF of more than a 1-year duration (phase 1). Next, the same questionnaire was performed again after providing the ML model's answer (phase 2). Subsequently, another 10 cardiologists (group B) were shown the test results of group A, were made aware of the limitations of their own diagnostic abilities, and were then administered the same 2-stage test as group A.
resultsThe prediction results with the ML model using the test data provided 81.8% accuracy (72% sensitivity and 89% specificity). The mean percentage of correct answers in group A was 63.9% (SD 9.6%) for phase 1 and improved to 71.6% (SD 9.3%) for phase 2 (P=.01). The mean percentage of correct answers in group B was 59.8% (SD 5.3%) for phase 1 and improved to 68.2% (SD 5.9%) for phase 2 (P=.007). The mean percentage of answers that differed from the ML model's prediction for phase 2 (percentage of answers where cardiologists did not trust the ML model and believed their own determination) was 17.3% (SD 10.3%) in group A and 20.9% (SD 5%) in group B and was not significantly different (P=.85).
conclusionsML models predicting AF duration improved the diagnostic ability of cardiologists. However, cardiologists did not entirely rely on the ML model's prediction, even if they were aware of their diagnostic capability limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.